TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from BB Biotech ( (CH:BION) ).
BB Biotech AG announced a disclosure of shareholdings, revealing that Saba Capital Management, L.P. has acquired a stake in the company, with voting rights totaling 5.004%. This acquisition indicates a strategic interest from Saba Capital Management in BB Biotech AG, potentially impacting the company’s market position and signaling confidence in its future prospects.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is a company operating in the biotechnology industry, focusing on investments in the biotechnology sector. It is known for its strategic investments in biotech companies, aiming to capitalize on the growth and innovation within the industry.
YTD Price Performance: -4.65%
Average Trading Volume: 84,495
Technical Sentiment Signal: Sell
Current Market Cap: CHF1.76B
Learn more about BION stock on TipRanks’ Stock Analysis page.